Wall Street brokerages forecast that Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) will announce $43.40 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Vanda Pharmaceuticals’ earnings. The highest sales estimate is $44.70 million and the lowest is $42.00 million. Vanda Pharmaceuticals reported sales of $37.42 million in the same quarter last year, which would suggest a positive year over year growth rate of 16%. The firm is scheduled to report its next earnings report on Tuesday, May 1st.
On average, analysts expect that Vanda Pharmaceuticals will report full year sales of $43.40 million for the current financial year, with estimates ranging from $190.60 million to $193.80 million. For the next fiscal year, analysts anticipate that the business will report sales of $237.67 million per share, with estimates ranging from $223.00 million to $262.60 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that cover Vanda Pharmaceuticals.
Vanda Pharmaceuticals (NASDAQ:VNDA) last released its earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.12) by $0.08. Vanda Pharmaceuticals had a negative net margin of 9.43% and a negative return on equity of 11.94%. The company had revenue of $44.28 million during the quarter, compared to analysts’ expectations of $44.00 million. During the same quarter last year, the business earned $0.08 EPS. The business’s revenue was up 15.8% on a year-over-year basis.
In other news, CFO James Patrick Kelly sold 9,155 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $15.35, for a total value of $140,529.25. Following the completion of the transaction, the chief financial officer now owns 144,721 shares in the company, valued at approximately $2,221,467.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Mihael Hristos Polymeropoulos sold 191,760 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $15.30, for a total transaction of $2,933,928.00. Following the completion of the transaction, the insider now owns 1,031,848 shares of the company’s stock, valued at approximately $15,787,274.40. The disclosure for this sale can be found here. Insiders sold a total of 287,506 shares of company stock valued at $4,665,795 in the last quarter. Insiders own 7.60% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Teacher Retirement System of Texas purchased a new position in Vanda Pharmaceuticals during the 4th quarter valued at about $209,000. Metropolitan Life Insurance Co. NY purchased a new position in Vanda Pharmaceuticals during the 4th quarter valued at about $221,000. Los Angeles Capital Management & Equity Research Inc. purchased a new position in Vanda Pharmaceuticals during the 3rd quarter valued at about $277,000. Voya Investment Management LLC increased its holdings in Vanda Pharmaceuticals by 29.7% during the 2nd quarter. Voya Investment Management LLC now owns 20,118 shares of the biopharmaceutical company’s stock valued at $328,000 after acquiring an additional 4,605 shares in the last quarter. Finally, MetLife Investment Advisors LLC purchased a new position in Vanda Pharmaceuticals during the 4th quarter valued at about $308,000. Institutional investors and hedge funds own 89.96% of the company’s stock.
Vanda Pharmaceuticals (NASDAQ VNDA) traded up $0.45 during mid-day trading on Wednesday, hitting $19.90. 531,094 shares of the stock traded hands, compared to its average volume of 715,584. Vanda Pharmaceuticals has a one year low of $11.90 and a one year high of $20.05. The firm has a market cap of $883.77, a PE ratio of -58.53 and a beta of 1.02.
TRADEMARK VIOLATION WARNING: This report was reported by Week Herald and is the property of of Week Herald. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://weekherald.com/2018/03/10/43-40-million-in-sales-expected-for-vanda-pharmaceuticals-inc-vnda-this-quarter.html.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.